搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
abp LIVE
10 小时
What Is Gastroparesis? Unraveling This Digestive Disorder And Its Impact On Health | Health ...
Experts indicate that this rare disorder can lead to various uncomfortable symptoms, including nausea, vomiting, bloating, ...
Medpage Today on MSN
2 天
FDA Rejects NK1R Antagonist for Gastroparesis
Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...
Zacks.com on MSN
22 小时
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...
pharmaphorum
1 天
Vanda slams FDA rejection of gastroparesis drug
The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...
Onlymyhealth
7 天
Why Does Gastroparesis Cause Challenges In Diagnosis, Treatment?
Gastroparesis is an often overlooked digestive disorder that significantly impacts the quality of life of those affected.
1 天
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesisSOLANA BEACH, Calif., Sept.
The Pharma Letter
1 天
FDA snubs Vanda Pharma's NDA for tradipitant in gastroparesis
Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...
BioWorld
2 天
US FDA issues CRL for Vanda’s tradipitant for gastroparesis
Clearly frustrated by the U.S. FDA’s rejection of tradipitant to treat gastroparesis, Vanda Pharmaceuticals Inc. CEO Mihael Polymeropoulos said the agency is discouraging drug development for the ...
1 天
on MSN
US FDA declines to approve Vanda's stomach condition drug
Vanda was seeking the health regulator's nod for the drug, tradipitant, to treat symptoms of gastroparesis, a condition ...
2 天
FDA rejects Vanda Pharmaceuticals' application to bring key drug to market
A D.C. drugmaker has been dealt a major setback in its long-running bid to bring its treatment for a chronic gastrointestinal ...
2 天
on MSN
Vanda slips as FDA rejects therapy for stomach condition
Vanda Pharmaceuticals (VNDA) stock saw a 9% premarket drop after FDA rejection of its therapy for gastroparesis, citing need ...
1 天
Evoke Pharma, Inc.: Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis ...
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈